Sorrento Therapeutics Inc (SRNE)

[HeadsIwin]

“Sorrento Therapeutics, wholly owned subsidiary of ACEA, which is developing multiple clinical and preclinical-stage new chemical entity compounds, including the late clinical drug candidate, Abivertinib.”
“Abivertinib – A Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases ($61B Market)”
“More than 600 patients have been treated with Abivertinib at different oral doses up to 300 mg bid in multiple trials through registration trial (NCT03856697) in patients with non-small cell lung cancer (NSCLC) and B cell malignancies (Phase 1) conducted in China. Favorable safety, tolerability and efficacy in patients with NSCLC or relapsed/refractory B-cell malignancies were demonstrated in the studies.
Abivertinib is also being tested as a potential treatment for cytokine storm associated with COVID-19 and as a potential treatment for cytokine release syndrome associated with CAR-T.”